Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010

Marcus A. Bachhuber, Brendan Saloner, Chinazo O. Cunningham, Colleen L. Barry

Research output: Contribution to journalArticle

287 Citations (Scopus)

Abstract

Importance: Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them.

Objective: To determine the association between the presence of state medical cannabis laws and opioid analgesic overdose mortality.

Design, Setting, and Participants: A time-series analysiswas conducted of medical cannabis laws and state-level death certificate data in the United States from 1999 to 2010; all 50 states were included.

Exposures: Presence of a law establishing a medical cannabis program in the state.

Main Outcomes and Measures: Age-adjusted opioid analgesic overdose death rate per 100 000 population in each state. Regression models were developed including state and year fixed effects, the presence of 3 different policies regarding opioid analgesics, and the state-specific unemployment rate.

Results: Three states (California, Oregon, andWashington) had medical cannabis laws effective prior to 1999. Ten states (Alaska, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Mexico, Rhode Island, and Vermont) enacted medical cannabis laws between 1999 and 2010. States with medical cannabis laws had a 24.8%lower mean annual opioid overdose mortality rate (95%CI, ?37.5%to ?9.5%; P = .003) compared with states without medical cannabis laws. Examination of the association between medical cannabis laws and opioid analgesic overdose mortality in each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time: year 1 (?19.9%; 95%CI, ?30.6%to ?7.7%; P = .002), year 2 (?25.2%; 95%CI, ?40.6%to ?5.9%; P = .01), year 3 (?23.6%; 95%CI, ?41.1% to ?1.0%; P = .04), year 4 (?20.2%; 95%CI, ?33.6%to ?4.0%; P = .02), year 5 (?33.7%; 95%CI, ?50.9%to ?10.4%; P = .008), and year 6 (?33.3%; 95%CI, ?44.7%to ?19.6%; P < .001). In secondary analyses, the findings remained similar.

Conclusions and Relevance: Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. Further investigation is required to determine how medical cannabis laws may interact with policies aimed at preventing opioid analgesic overdose.

Original languageEnglish (US)
Pages (from-to)1668-1673
Number of pages6
JournalJAMA Internal Medicine
Volume174
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Medical Marijuana
Opioid Analgesics
Mortality
Chronic Pain
Death Certificates
Unemployment

ASJC Scopus subject areas

  • Internal Medicine
  • Medicine(all)

Cite this

Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. / Bachhuber, Marcus A.; Saloner, Brendan; Cunningham, Chinazo O.; Barry, Colleen L.

In: JAMA Internal Medicine, Vol. 174, No. 10, 01.10.2014, p. 1668-1673.

Research output: Contribution to journalArticle

Bachhuber, Marcus A. ; Saloner, Brendan ; Cunningham, Chinazo O. ; Barry, Colleen L. / Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. In: JAMA Internal Medicine. 2014 ; Vol. 174, No. 10. pp. 1668-1673.
@article{d7ca07ac72ff4dc7a9659def312e2bf5,
title = "Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010",
abstract = "Importance: Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them.Objective: To determine the association between the presence of state medical cannabis laws and opioid analgesic overdose mortality.Design, Setting, and Participants: A time-series analysiswas conducted of medical cannabis laws and state-level death certificate data in the United States from 1999 to 2010; all 50 states were included.Exposures: Presence of a law establishing a medical cannabis program in the state.Main Outcomes and Measures: Age-adjusted opioid analgesic overdose death rate per 100 000 population in each state. Regression models were developed including state and year fixed effects, the presence of 3 different policies regarding opioid analgesics, and the state-specific unemployment rate.Results: Three states (California, Oregon, andWashington) had medical cannabis laws effective prior to 1999. Ten states (Alaska, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Mexico, Rhode Island, and Vermont) enacted medical cannabis laws between 1999 and 2010. States with medical cannabis laws had a 24.8{\%}lower mean annual opioid overdose mortality rate (95{\%}CI, ?37.5{\%}to ?9.5{\%}; P = .003) compared with states without medical cannabis laws. Examination of the association between medical cannabis laws and opioid analgesic overdose mortality in each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time: year 1 (?19.9{\%}; 95{\%}CI, ?30.6{\%}to ?7.7{\%}; P = .002), year 2 (?25.2{\%}; 95{\%}CI, ?40.6{\%}to ?5.9{\%}; P = .01), year 3 (?23.6{\%}; 95{\%}CI, ?41.1{\%} to ?1.0{\%}; P = .04), year 4 (?20.2{\%}; 95{\%}CI, ?33.6{\%}to ?4.0{\%}; P = .02), year 5 (?33.7{\%}; 95{\%}CI, ?50.9{\%}to ?10.4{\%}; P = .008), and year 6 (?33.3{\%}; 95{\%}CI, ?44.7{\%}to ?19.6{\%}; P < .001). In secondary analyses, the findings remained similar.Conclusions and Relevance: Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. Further investigation is required to determine how medical cannabis laws may interact with policies aimed at preventing opioid analgesic overdose.",
author = "Bachhuber, {Marcus A.} and Brendan Saloner and Cunningham, {Chinazo O.} and Barry, {Colleen L.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1001/jamainternmed.2014.4005",
language = "English (US)",
volume = "174",
pages = "1668--1673",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010

AU - Bachhuber, Marcus A.

AU - Saloner, Brendan

AU - Cunningham, Chinazo O.

AU - Barry, Colleen L.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Importance: Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them.Objective: To determine the association between the presence of state medical cannabis laws and opioid analgesic overdose mortality.Design, Setting, and Participants: A time-series analysiswas conducted of medical cannabis laws and state-level death certificate data in the United States from 1999 to 2010; all 50 states were included.Exposures: Presence of a law establishing a medical cannabis program in the state.Main Outcomes and Measures: Age-adjusted opioid analgesic overdose death rate per 100 000 population in each state. Regression models were developed including state and year fixed effects, the presence of 3 different policies regarding opioid analgesics, and the state-specific unemployment rate.Results: Three states (California, Oregon, andWashington) had medical cannabis laws effective prior to 1999. Ten states (Alaska, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Mexico, Rhode Island, and Vermont) enacted medical cannabis laws between 1999 and 2010. States with medical cannabis laws had a 24.8%lower mean annual opioid overdose mortality rate (95%CI, ?37.5%to ?9.5%; P = .003) compared with states without medical cannabis laws. Examination of the association between medical cannabis laws and opioid analgesic overdose mortality in each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time: year 1 (?19.9%; 95%CI, ?30.6%to ?7.7%; P = .002), year 2 (?25.2%; 95%CI, ?40.6%to ?5.9%; P = .01), year 3 (?23.6%; 95%CI, ?41.1% to ?1.0%; P = .04), year 4 (?20.2%; 95%CI, ?33.6%to ?4.0%; P = .02), year 5 (?33.7%; 95%CI, ?50.9%to ?10.4%; P = .008), and year 6 (?33.3%; 95%CI, ?44.7%to ?19.6%; P < .001). In secondary analyses, the findings remained similar.Conclusions and Relevance: Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. Further investigation is required to determine how medical cannabis laws may interact with policies aimed at preventing opioid analgesic overdose.

AB - Importance: Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them.Objective: To determine the association between the presence of state medical cannabis laws and opioid analgesic overdose mortality.Design, Setting, and Participants: A time-series analysiswas conducted of medical cannabis laws and state-level death certificate data in the United States from 1999 to 2010; all 50 states were included.Exposures: Presence of a law establishing a medical cannabis program in the state.Main Outcomes and Measures: Age-adjusted opioid analgesic overdose death rate per 100 000 population in each state. Regression models were developed including state and year fixed effects, the presence of 3 different policies regarding opioid analgesics, and the state-specific unemployment rate.Results: Three states (California, Oregon, andWashington) had medical cannabis laws effective prior to 1999. Ten states (Alaska, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Mexico, Rhode Island, and Vermont) enacted medical cannabis laws between 1999 and 2010. States with medical cannabis laws had a 24.8%lower mean annual opioid overdose mortality rate (95%CI, ?37.5%to ?9.5%; P = .003) compared with states without medical cannabis laws. Examination of the association between medical cannabis laws and opioid analgesic overdose mortality in each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time: year 1 (?19.9%; 95%CI, ?30.6%to ?7.7%; P = .002), year 2 (?25.2%; 95%CI, ?40.6%to ?5.9%; P = .01), year 3 (?23.6%; 95%CI, ?41.1% to ?1.0%; P = .04), year 4 (?20.2%; 95%CI, ?33.6%to ?4.0%; P = .02), year 5 (?33.7%; 95%CI, ?50.9%to ?10.4%; P = .008), and year 6 (?33.3%; 95%CI, ?44.7%to ?19.6%; P < .001). In secondary analyses, the findings remained similar.Conclusions and Relevance: Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. Further investigation is required to determine how medical cannabis laws may interact with policies aimed at preventing opioid analgesic overdose.

UR - http://www.scopus.com/inward/record.url?scp=84907990276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907990276&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2014.4005

DO - 10.1001/jamainternmed.2014.4005

M3 - Article

C2 - 25154332

AN - SCOPUS:84907990276

VL - 174

SP - 1668

EP - 1673

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 10

ER -